Rationale and design of the 52-week, randomized, phase 3, head-to-head mandara study to evaluate the efficacy and safety of benralizumab, a humanized, anti-interleukin-5 receptor. monoclonal antibody in refractory or relapsing eosinophilic granulomatosis with polyangiitis